Clinical trial
A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BIIB092 in Patients With Progressive Supranuclear Palsy Who Participated in Study CN002003
NCT02658916 is registered in ClinicalTrials.gov with Biogen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BIIB092 in Patients With Progressive Supranuclear Palsy Who Participated in Study CN002003
- Lead sponsor
- Biogen
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- February 22, 2016
- Completion date
- March 31, 2020
- Enrollment
- 47 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.